Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406287 · ClinicalTrials.gov registry record · Phase 1
A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers
A Phase 1 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02406287: Completed Phase 1 study, sponsored by Aerie Pharmaceuticals.
NCT02406287 is a Phase 1 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02406287, a Phase 1 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
To evaluate the effect of netarsudil (AR-13324) ophthalmic solution on aqueous humor dynamics relative to its placebo.
Primary Outcome
Aqueous humor flow rate measured by non-contact fluorophotometer; change from baseline
Interventions
- DRUG Netarsudil (AR-13324) Ophthalmic Solution
- DRUG Netarsudil (AR-13324) Ophthalmic Solution Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT02406287 record still lists
NCT02406287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Netarsudil (AR-13324) Ophthalmic Solution is the first listed.
NCT02406287 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02406287 about?
NCT02406287 is a clinical study titled "A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers". To evaluate the effect of netarsudil (AR-13324) ophthalmic solution on aqueous humor dynamics relative to its placebo.
What is the current status of trial NCT02406287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-04. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02406287?
The interventions under investigation include: Netarsudil (AR-13324) Ophthalmic Solution (DRUG), Netarsudil (AR-13324) Ophthalmic Solution Placebo (DRUG).
Who is sponsoring clinical trial NCT02406287?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02406287's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia